Bone disease in multiple myeloma: New markers, new treatments

Internal Medicine Journal

Volumn 31, Issue 5, 2001, Pages 261-263

  Joshua, D ^a  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BIOCHEMICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; PAMIDRONIC ACID; PYROPHOSPHATE;

AMINO TERMINAL SEQUENCE; ANTINEOPLASTIC ACTIVITY; BONE DISEASE; BONE PAIN; BONE TURNOVER; DISEASE MARKER; DRUG EFFICACY; EDITORIAL; FRACTURE; HUMAN; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; NAUSEA; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; PLASMA CELL; PRIORITY JOURNAL; VOMITING;

BONE NEOPLASMS; DIPHOSPHONATES; HUMANS; MULTIPLE MYELOMA; TUMOR MARKERS, BIOLOGICAL;

EID: 0034903629     PISSN: 14440903     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1445-5994.2001.00073.x     Document Type: Editorial

References (21)

1. Multiple myeloma: Review of 869 cases
2. Multiple myeloma: Evolving concepts of biology and treatment
3. The hypercalcemia of cancer. Clinical implications and pathogenic mechanisms
4. Bone disease in myeloma
5. Production of lymphotoxin, a bone resorbing cytokine, by cultured human myeloma cells
6. Interleukin-1 beta rather than lymphotoxin as a major bone resorbing activity in human multiple myeloma
7. Parathyroid hormone-related protein in hypercalcaemia associated with haematological malignancy
8. Secretion of parathyroid hormone-related peptide in patients with multiple myeloma
9. Prognostic value of serum markers of bone metabolism in untreated myeloma patients
10. Biochemical markers of bone turnover following high-dose chemotherapy and autografting in multiple myeloma
11. Noninvasive markers of bone turnover and plasma cytokines differ in osteoporotic patients with multiple myeloma and monoclonal gammopathies of undetermined significance
12. Bisphosphonates: Mechanisms of action
13. Clodronate and liposome-encapsulated clodronate are metabolized to a toxic ATP analog, adenosine 5′-(beta, gamma-dichlormethylene) triphosphonate, by mammalian cells in vitro
14. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras
15. A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma
16. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma
17. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events
18. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: A pooled analysis of two randomized, controlled clinical trials
19. Anti-myeloma activity of pamidronate in vivo
20. Stilumation of γδ T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma
21. Zoledronate secretion of IL-6 and MMP-1 by the tumoral environment